# USMLE Step 1 Conditions Explorer - Master Roadmap

**Last Updated**: October 21, 2025
**Overall Progress**: 46.1% (228/495 diseases comprehensive)

---

## üìä EXECUTIVE DASHBOARD

| Status | Systems | Diseases | % Complete |
|--------|---------|----------|------------|
| ‚úÖ **Complete** | 5/19 (26%) | 201/495 (41%) | 100% |
| üü° **In Progress** | 1/19 (5%) | 27/36 (75%) | 75% |
| üî¥ **Needs Work** | 13/19 (68%) | 0/267 (0%) | 0% |

**Target**: All 495 diseases at Level 3 (Comprehensive)

---

## üéØ COMPLETION STANDARDS

### Level 1 - Placeholder ‚ùå
- Only `detail.definition` (1-2 sentence summary)
- `detail.overview: "[Content coming soon]"`

### Level 2 - Basic Complete üü°
- Definition + overview paragraph
- 3-6 additional fields: pathophysiology, epidemiology, presentation, management
- 2-3 clinical pearls

### Level 3 - Comprehensive ‚úÖ (TARGET)
Required fields:
- [x] `definition` - Concise 1-2 sentence summary
- [x] `pathophysiology` - Mechanism of disease
- [x] `epidemiology` - Incidence, prevalence, demographics
- [x] `riskFactors` - Array of risk factors
- [x] `presentation` - Clinical presentation
- [x] `physicalExam` - Array of exam findings
- [x] `diagnosticCriteria` - Formal diagnostic criteria
- [x] `labs` - Array of lab findings
- [x] `imaging` - Array of imaging findings
- [x] `differentialDiagnosis` - Array of 3-5 alternatives
- [x] `management.acute` - Array of acute treatment steps
- [x] `management.chronic` - Array of chronic management steps
- [x] `complications` - Array of complications
- [x] `prognosis` - Outcome information
- [x] `clinicalPearls` - Array of 5-10 high-yield points for USMLE

---

## üöÄ PHASE 1: FINISH IN-PROGRESS (Priority 1)

### üü° Gastrointestinal System
**File**: `gi-diseases.js`
**Progress**: 27/36 complete (75%)
**Remaining**: 9 diseases

#### Objectives:
- [ ] Expand NAFLD (nafld) to Level 3
- [ ] Expand Hepatocellular Carcinoma (hepatocellular-carcinoma) to Level 3
- [ ] Expand Hemorrhoids (hemorrhoids) to Level 3
- [ ] Expand Gastric Cancer (gastric-cancer) to Level 3
- [ ] Expand Angiodysplasia (angiodysplasia) to Level 3
- [ ] Expand Chronic Pancreatitis (chronic-pancreatitis) to Level 3
- [ ] Expand Esophageal Cancer (esophageal-cancer) to Level 3
- [ ] Expand Ischemic Colitis (ischemic-colitis) to Level 3
- [ ] Expand Gastroparesis (gastroparesis) to Level 3

**Estimated Time**: 9 diseases √ó 45 min = 6.75 hours
**Target Completion**: Week 1

---

## üî• PHASE 2: HIGH-YIELD SYSTEMS (Priority 2)

### 1Ô∏è‚É£ Neurology System ‚≠ê‚≠ê‚≠ê
**File**: `neurology-diseases.js`
**Progress**: 0/33 complete (0%)
**Format**: Multi-line (good)

#### Objectives:
Expand ALL 33 diseases to Level 3:
- [ ] migraine
- [ ] tension-headache
- [ ] cluster-headache
- [ ] ischemic-stroke
- [ ] hemorrhagic-stroke
- [ ] tia
- [ ] parkinsons-disease
- [ ] essential-tremor
- [ ] alzheimers-disease
- [ ] vascular-dementia
- [ ] multiple-sclerosis
- [ ] myasthenia-gravis
- [ ] guillain-barre-syndrome
- [ ] bacterial-meningitis
- [ ] viral-meningitis
- [ ] glioblastoma
- [ ] subarachnoid-hemorrhage
- [ ] temporal-arteritis
- [ ] seizure-generalized-tonic-clonic
- [ ] absence-seizure
- [ ] huntingtons-disease
- [ ] lewy-body-dementia
- [ ] frontotemporal-dementia
- [ ] amyotrophic-lateral-sclerosis
- [ ] peripheral-neuropathy
- [ ] bells-palsy
- [ ] charcot-marie-tooth
- [ ] hsv-encephalitis
- [ ] brain-abscess
- [ ] meningioma
- [ ] metastatic-brain-tumors
- [ ] narcolepsy
- [ ] restless-legs-syndrome

**Estimated Time**: 33 diseases √ó 45 min = 24.75 hours
**Target Completion**: Week 2-4

---

### 2Ô∏è‚É£ Infectious Disease System ‚≠ê‚≠ê‚≠ê
**File**: `infectious-disease-diseases.js`
**Progress**: 0/24 complete (0%)
**Format**: Multi-line (good)

#### Objectives:
Expand ALL 24 diseases to Level 3:
- [ ] community-acquired-pneumonia
- [ ] urinary-tract-infection
- [ ] pyelonephritis
- [ ] clostridioides-difficile-colitis
- [ ] cellulitis
- [ ] necrotizing-fasciitis
- [ ] hiv-aids
- [ ] syphilis
- [ ] endocarditis
- [ ] sepsis-septic-shock
- [ ] fever-unknown-origin
- [ ] pneumocystis-pneumonia
- [ ] cytomegalovirus
- [ ] cryptococcal-meningitis
- [ ] toxoplasma-encephalitis
- [ ] mycobacterium-avium-complex
- [ ] osteomyelitis
- [ ] gastroenteritis-infectious
- [ ] malaria
- [ ] dengue-fever
- [ ] typhoid-fever
- [ ] chlamydia-gonorrhea
- [ ] herpes-simplex-genital
- [ ] lyme-disease

**Estimated Time**: 24 diseases √ó 45 min = 18 hours
**Target Completion**: Week 5-6

---

### 3Ô∏è‚É£ Endocrine System ‚≠ê‚≠ê‚≠ê
**File**: `endocrine-diseases.js`
**Progress**: 0/22 complete (0%)
**Format**: Multi-line (good)

#### Objectives:
Expand ALL 22 diseases to Level 3:
- [ ] hypothyroidism
- [ ] hyperthyroidism
- [ ] graves-disease
- [ ] hashimoto-thyroiditis
- [ ] diabetes-type-1
- [ ] diabetes-type-2
- [ ] diabetic-ketoacidosis
- [ ] hyperosmolar-hyperglycemic-state
- [ ] cushing-syndrome
- [ ] addison-disease
- [ ] primary-hyperaldosteronism
- [ ] pheochromocytoma
- [ ] acromegaly
- [ ] prolactinoma
- [ ] diabetes-insipidus
- [ ] siadh
- [ ] hypopituitarism
- [ ] hyperparathyroidism
- [ ] hypoparathyroidism
- [ ] osteoporosis
- [ ] osteomalacia
- [ ] pagets-disease

**Estimated Time**: 22 diseases √ó 45 min = 16.5 hours
**Target Completion**: Week 7-8

---

### 4Ô∏è‚É£ Rheumatology System ‚≠ê‚≠ê
**File**: `rheumatology-diseases.js`
**Progress**: 0/24 complete (0%)
**Format**: Multi-line (good)

#### Objectives:
Expand ALL 24 diseases to Level 3:
- [ ] rheumatoid-arthritis
- [ ] osteoarthritis
- [ ] gout
- [ ] pseudogout
- [ ] septic-arthritis
- [ ] reactive-arthritis
- [ ] systemic-lupus-erythematosus
- [ ] sjogren-syndrome
- [ ] scleroderma
- [ ] polymyositis-dermatomyositis
- [ ] mixed-connective-tissue-disease
- [ ] ankylosing-spondylitis
- [ ] psoriatic-arthritis
- [ ] giant-cell-arteritis
- [ ] takayasu-arteritis
- [ ] polyarteritis-nodosa
- [ ] granulomatosis-with-polyangiitis
- [ ] eosinophilic-granulomatosis-with-polyangiitis
- [ ] microscopic-polyangiitis
- [ ] henoch-schonlein-purpura
- [ ] kawasaki-disease
- [ ] behcet-disease
- [ ] fibromyalgia-rheum
- [ ] polymyalgia-rheumatica

**Estimated Time**: 24 diseases √ó 45 min = 18 hours
**Target Completion**: Week 9-10

---

## üìã PHASE 3: MEDIUM-YIELD SYSTEMS (Priority 3)

### 5Ô∏è‚É£ Musculoskeletal System ‚≠ê
**File**: `musculoskeletal-diseases.js`
**Progress**: 0/22 complete (0%)
**Diseases**: 22

**Estimated Time**: 16.5 hours
**Target**: Week 11-12

---

### 6Ô∏è‚É£ ENT System ‚≠ê
**File**: `ent-diseases.js`
**Progress**: 0/28 complete (0%)
**Format**: ‚ö†Ô∏è Single-line (needs conversion to multi-line)
**Diseases**: 28

#### Additional Objective:
- [ ] **Convert from single-line to multi-line format** before expanding

**Estimated Time**: 21 hours (+ 2 hours format conversion)
**Target**: Week 13-15

---

### 7Ô∏è‚É£ Dermatology System ‚≠ê
**File**: `dermatology-diseases.js`
**Progress**: 0/24 complete (0%)
**Diseases**: 24

**Estimated Time**: 18 hours
**Target**: Week 16-17

---

### 8Ô∏è‚É£ Reproductive/OBGYN System ‚≠ê
**File**: `reproductive-obgyn-diseases.js`
**Progress**: 0/15 complete (0%)
**Diseases**: 15

**Estimated Time**: 11.25 hours
**Target**: Week 18-19

---

## üìå PHASE 4: LOWER-PRIORITY SYSTEMS (Priority 4)

### 9Ô∏è‚É£ Genitourinary System
**File**: `genitourinary-diseases.js`
**Diseases**: 19
**Estimated Time**: 14.25 hours
**Target**: Week 20-21

---

### üîü Ophthalmology System
**File**: `ophthalmology-diseases.js`
**Diseases**: 12
**Format**: ‚ö†Ô∏è Single-line ‚Üí Multi-line conversion needed
**Estimated Time**: 9 hours + 1 hour conversion
**Target**: Week 22

---

### 1Ô∏è‚É£1Ô∏è‚É£ Toxicology System
**File**: `toxicology-diseases.js`
**Diseases**: 11
**Format**: ‚ö†Ô∏è Single-line ‚Üí Multi-line conversion needed
**Estimated Time**: 8.25 hours + 1 hour conversion
**Target**: Week 23

---

### 1Ô∏è‚É£2Ô∏è‚É£ Immunology System
**File**: `immunology-diseases.js`
**Diseases**: 9
**Format**: ‚ö†Ô∏è Single-line ‚Üí Multi-line conversion needed
**Estimated Time**: 6.75 hours + 1 hour conversion
**Target**: Week 24

---

### 1Ô∏è‚É£3Ô∏è‚É£ Pediatrics System
**File**: `pediatrics-diseases.js`
**Diseases**: 15
**Format**: ‚ö†Ô∏è Single-line ‚Üí Multi-line conversion needed
**Estimated Time**: 11.25 hours + 1 hour conversion
**Target**: Week 25

---

## üìù PHASE 5: FORMAT STANDARDIZATION

### Objective:
Convert 5 systems from single-line to multi-line object format for better readability and maintainability.

#### Files to Convert:
1. [ ] `ent-diseases.js` (28 diseases)
2. [ ] `ophthalmology-diseases.js` (12 diseases)
3. [ ] `toxicology-diseases.js` (11 diseases)
4. [ ] `immunology-diseases.js` (9 diseases)
5. [ ] `pediatrics-diseases.js` (15 diseases)

**Total Diseases**: 75
**Estimated Time**: 5 hours
**Target**: Integrated into respective phase work

---

## üìö CATEGORY PAGES ROADMAP

### Current State:
Category pages are referenced in disease files but many need to be created/populated.

### Objectives:

#### Step 1: Inventory All Categories
- [ ] Extract all unique category IDs from all disease files
- [ ] Cross-reference with existing category definitions
- [ ] Identify missing category pages

#### Step 2: Define Category Page Standards
Each category page should have:
- [ ] `id` - Category identifier
- [ ] `name` - Display name
- [ ] `system` - Parent system
- [ ] `description` - What this category covers
- [ ] `clinicalApproach` - How to approach diseases in this category
- [ ] `keyDifferentiators` - How to differentiate diseases within category
- [ ] `diagnosticFramework` - General diagnostic approach
- [ ] `diseaseList` - Auto-populated from disease files

#### Step 3: Create Missing Category Pages
- [ ] Cardiovascular categories (15-20 categories)
- [ ] Respiratory categories (8-10 categories)
- [ ] Gastrointestinal categories (10-12 categories)
- [ ] Neurology categories (8-10 categories)
- [ ] Endocrine categories (6-8 categories)
- [ ] Infectious Disease categories (8-10 categories)
- [ ] Hematology/Oncology categories (15-20 categories)
- [ ] Renal categories (6-8 categories)
- [ ] Musculoskeletal categories (8-10 categories)
- [ ] Rheumatology categories (6-8 categories)
- [ ] Dermatology categories (8-10 categories)
- [ ] Psychiatry categories (10-12 categories)
- [ ] OBGYN categories (6-8 categories)
- [ ] Genitourinary categories (6-8 categories)
- [ ] ENT categories (8-10 categories)
- [ ] Ophthalmology categories (6-8 categories)
- [ ] Pediatrics categories (6-8 categories)
- [ ] Immunology categories (4-6 categories)
- [ ] Toxicology categories (4-6 categories)

**Estimated Categories**: ~150-200 category pages
**Estimated Time**: 75-100 hours
**Target**: After Phase 2 completion

---

## üéØ OVERALL TIMELINE

| Phase | Content | Duration | Completion |
|-------|---------|----------|------------|
| **Phase 1** | GI (9 diseases) | Week 1 | 0% |
| **Phase 2** | High-Yield (103 diseases) | Weeks 2-10 | 0% |
| **Phase 3** | Medium-Yield (89 diseases) | Weeks 11-19 | 0% |
| **Phase 4** | Lower-Priority (66 diseases) | Weeks 20-25 | 0% |
| **Phase 5** | Format Standardization | Integrated | 0% |
| **Phase 6** | Category Pages | Weeks 26-40 | 0% |

**Total Project Duration**: ~40 weeks (at 4-6 hours/week)
**Total Work Hours**: ~200-250 hours

---

## üìà SUCCESS METRICS

### Disease Content Quality:
- [ ] 100% of diseases at Level 3 (comprehensive)
- [ ] All diseases follow consistent structure
- [ ] All diseases have 8+ detail fields
- [ ] All diseases have 5-10 clinical pearls
- [ ] All diseases peer-reviewed for accuracy

### Category Pages:
- [ ] All categories have comprehensive landing pages
- [ ] All categories have clinical approach frameworks
- [ ] All categories have key differentiators

### Overall System:
- [ ] Zero placeholder content ("[Content coming soon]")
- [ ] Consistent multi-line object format across all files
- [ ] No duplicate diseases across systems
- [ ] All cross-references correctly linked via categories

---

## üîÑ WEEKLY WORKFLOW

### Week Structure:
1. **Monday**: Select 6-8 diseases from current phase
2. **Tuesday-Thursday**: Expand diseases to Level 3 (2-3 per day)
3. **Friday**: Review, quality check, commit changes
4. **Saturday**: Update roadmap, track progress

### Quality Checklist (per disease):
- [ ] All 14 required fields present
- [ ] Pathophysiology scientifically accurate
- [ ] Management aligned with current guidelines
- [ ] Clinical pearls high-yield for USMLE Step 1
- [ ] No spelling/grammar errors
- [ ] Consistent formatting with system conventions

---

## üìû NEXT STEPS

### Immediate Action Items:
1. [ ] Review and approve this roadmap
2. [ ] Start Phase 1: Complete remaining 9 GI diseases
3. [ ] Set up tracking system for progress monitoring
4. [ ] Establish review/QA process for completed content

### Questions to Resolve:
- What's the target completion date for the entire project?
- Should we work sequentially or allow parallel work on multiple systems?
- Do we need medical review/validation for clinical accuracy?
- Should we prioritize based on USMLE Step 1 blueprint percentages?

---

---

## üß¨ PHASE 7: PHYSIOLOGY & ANATOMY EXPLORERS (Future Expansion)

### Objective:
Expand the platform beyond clinical diseases to include foundational basic science content, creating separate explorers for **Physiology** and **Anatomy**.

### Architecture: Separate Explorers (Option A)

```
Step 1 Medical Explorers/
‚îú‚îÄ‚îÄ Conditions Explorer (diseases/pathology only)
‚îÇ   ‚îî‚îÄ‚îÄ System ‚Üí Categories ‚Üí Diseases
‚îú‚îÄ‚îÄ Medications Explorer (pharmacology)
‚îÇ   ‚îî‚îÄ‚îÄ Drug classes ‚Üí Individual drugs
‚îú‚îÄ‚îÄ Bugs Explorer (microbiology)
‚îÇ   ‚îî‚îÄ‚îÄ Organism types ‚Üí Individual pathogens
‚îú‚îÄ‚îÄ Physiology Explorer (normal function) ‚Üê NEW
‚îÇ   ‚îî‚îÄ‚îÄ System ‚Üí Physiology topics
‚îÇ       ‚îî‚îÄ‚îÄ Endocrine ‚Üí Insulin Secretion Regulation
‚îÇ       ‚îî‚îÄ‚îÄ Cardiovascular ‚Üí Cardiac Action Potential
‚îÇ       ‚îî‚îÄ‚îÄ Renal ‚Üí Acid-Base Regulation
‚îî‚îÄ‚îÄ Anatomy Explorer (structure) ‚Üê FUTURE
    ‚îî‚îÄ‚îÄ System ‚Üí Anatomical regions/structures
        ‚îî‚îÄ‚îÄ Endocrine ‚Üí Pancreatic Anatomy & Histology
        ‚îî‚îÄ‚îÄ Cardiovascular ‚Üí Heart Anatomy
```

**Rationale:**
- ‚úÖ Each explorer has **one clear purpose** (disease vs normal function vs structure)
- ‚úÖ Maps to **medical education** structure (basic sciences vs clinical)
- ‚úÖ Matches **USMLE Step 1** content organization
- ‚úÖ **Scalable** - can add Biochemistry, Biostatistics explorers later
- ‚úÖ Students can study physiology **independently** or **via cross-links** from diseases
- ‚úÖ No naming confusion - "Conditions" stays focused on diseases only

---

### Physiology Explorer

#### Scope:
Normal physiologic function organized by organ system.

#### Content Structure:
Each physiology topic includes:
- **Overview** - Summary of normal physiology
- **Molecular/Cellular Mechanisms** - Detailed mechanistic explanations
- **Receptor Tables** - GPCR signaling, ion channels, etc.
- **Regulatory Pathways** - Feedback loops, homeostasis
- **Clinical Correlations** - How this relates to diseases and pharmacology
- **Related Diseases** - Cross-links to Conditions Explorer
- **Related Medications** - Cross-links to Medications Explorer

#### Example: Insulin Secretion Regulation

```javascript
{
    id: "insulin-secretion-regulation",
    name: "Insulin Secretion Regulation",
    system: "endocrine",
    categories: ["physiology", "beta-cell-physiology"],
    tags: ["physiology", "basic-science", "GPCR", "insulin"],
    pageType: "physiology",
    detail: {
        overview: "Pancreatic beta cells secrete insulin in response to glucose and various hormonal signals mediated by G-protein coupled receptors (GPCRs)...",

        receptorTable: `
## GPCR Regulation of Insulin Secretion

| Receptor | G alpha subunit | Effect on insulin secretion |
|----------|-----------------|----------------------------|
| Muscarinic M3 | Gq | ‚¨ÜÔ∏è Increased |
| Glucagon | Gs/Gq | ‚¨ÜÔ∏è Increased |
| Beta-2 adrenergic | Gs | ‚¨ÜÔ∏è Increased |
| GLP-1 | Gs | ‚¨ÜÔ∏è Increased |
| Alpha-2 adrenergic | Gi | ‚¨áÔ∏è Decreased |
| Somatostatin 2 | Gi | ‚¨áÔ∏è Decreased |

### Key Mechanisms:
- **Gs pathway**: Activates adenylyl cyclase ‚Üí ‚Üë cAMP ‚Üí ‚Üë PKA ‚Üí enhanced insulin secretion
- **Gq pathway**: Activates phospholipase C ‚Üí ‚Üë IP3/DAG ‚Üí ‚Üë Ca¬≤‚Å∫ ‚Üí enhanced insulin secretion
- **Gi pathway**: Inhibits adenylyl cyclase ‚Üí ‚Üì cAMP ‚Üí ‚Üì PKA ‚Üí suppressed insulin secretion
        `,

        glucoseStimuatedInsulinSecretion: "GLUCOSE METABOLISM ‚Üí ATP production ‚Üí closes K-ATP channels ‚Üí depolarization ‚Üí opens voltage-gated Ca¬≤‚Å∫ channels ‚Üí Ca¬≤‚Å∫ influx ‚Üí insulin granule exocytosis...",

        amplifyingPathways: "GLP-1 (Gs) and muscarinic M3 (Gq) receptors AMPLIFY glucose-stimulated insulin secretion. They do NOT trigger insulin release alone (glucose-dependent), making GLP-1 agonists safe (low hypoglycemia risk)...",

        inhibitoryPathways: "Alpha-2 adrenergic and somatostatin receptors (both Gi) SUPPRESS insulin secretion. Activated during stress (epinephrine), fasting (somatostatin), or by medications (alpha-2 agonists like clonidine)...",

        clinicalCorrelations: [
            "**GLP-1 agonists** (semaglutide, liraglutide, dulaglutide): Activate Gs pathway ‚Üí glucose-dependent insulin secretion ‚Üí T2DM treatment with LOW hypoglycemia risk",
            "**Alpha-2 agonists** (clonidine, dexmedetomidine): Activate Gi pathway ‚Üí SUPPRESS insulin ‚Üí can cause HYPERGLYCEMIA (important side effect)",
            "**Beta-blockers**: Block beta-2 receptors ‚Üí impair counterregulatory response to hypoglycemia ‚Üí MASK hypoglycemia symptoms (tachycardia, tremor)",
            "**Somatostatin analogs** (octreotide): Activate Gi pathway ‚Üí suppress insulin ‚Üí useful for INSULINOMA treatment (paradoxical - suppress tumor insulin secretion)",
            "**Atropine** (muscarinic antagonist): Blocks M3 receptors ‚Üí can reduce insulin secretion ‚Üí rarely causes hyperglycemia",
            "**Sulfonylureas** (glyburide, glipizide): Close K-ATP channels directly ‚Üí insulin release INDEPENDENT of glucose ‚Üí HIGH hypoglycemia risk (vs GLP-1)"
        ],

        relatedDiseases: [
            "type-1-diabetes-mellitus (autoimmune beta cell destruction ‚Üí NO insulin secretion)",
            "type-2-diabetes-mellitus (impaired beta cell function + insulin resistance)",
            "insulinoma (autonomous insulin secretion ‚Üí hypoglycemia)",
            "maturity-onset-diabetes-of-the-young (MODY - K-ATP channel mutations)"
        ],

        relatedMedications: [
            "glp1-agonists (semaglutide, liraglutide, dulaglutide)",
            "sulfonylureas (glyburide, glipizide, glimepiride)",
            "beta-blockers (metoprolol, propranolol, atenolol)",
            "alpha-2-agonists (clonidine, dexmedetomidine)",
            "somatostatin-analogs (octreotide, lanreotide)",
            "atropine"
        ],

        usmleHighYield: [
            "GLP-1 = Gs ‚Üí cAMP ‚Üë ‚Üí GLUCOSE-DEPENDENT insulin release (safe, low hypoglycemia)",
            "Alpha-2 agonists = Gi ‚Üí cAMP ‚Üì ‚Üí SUPPRESS insulin ‚Üí HYPERGLYCEMIA side effect",
            "Beta-blockers ‚Üí mask hypoglycemia symptoms (tachycardia, tremor) but NOT diaphoresis (cholinergic)",
            "Sulfonylureas bypass glucose ‚Üí NON-glucose-dependent ‚Üí HIGH hypoglycemia risk vs GLP-1",
            "Somatostatin = Gi ‚Üí suppress insulin ‚Üí treat insulinoma or acromegaly (suppress GH)",
            "Muscarinic M3 = Gq ‚Üí amplify glucose-stimulated insulin secretion"
        ]
    }
}
```

#### Estimated Physiology Topics by System:
- **Cardiovascular**: 15-20 topics (cardiac action potential, Frank-Starling, baroreceptor reflex, etc.)
- **Respiratory**: 10-12 topics (ventilation-perfusion matching, oxygen-hemoglobin curve, etc.)
- **Renal**: 15-18 topics (GFR regulation, acid-base, electrolyte handling, etc.)
- **Gastrointestinal**: 12-15 topics (gastric acid secretion, bile metabolism, etc.)
- **Endocrine**: 20-25 topics (HPT axis, HPA axis, insulin regulation, etc.)
- **Neurology**: 15-20 topics (action potentials, neurotransmitters, etc.)
- **Hematology**: 10-12 topics (coagulation cascade, hemoglobin synthesis, etc.)
- **Immunology**: 12-15 topics (complement, cytokines, MHC, etc.)

**Total Estimated Topics**: ~120-150 physiology topics
**Estimated Time**: 150-200 hours (45-60 min per topic)
**Target**: Phase 7 (after all conditions complete)

---

### Anatomy Explorer

#### Scope:
Gross anatomy, histology, and embryology organized by organ system.

#### Content Structure:
Each anatomy topic includes:
- **Gross Anatomy** - Macroscopic structure
- **Histology** - Microscopic structure and cell types
- **Embryology** - Developmental origin
- **Anatomical Relationships** - Spatial relationships with other structures
- **Clinical Correlations** - Anatomical basis of disease
- **Related Diseases** - Cross-links to conditions affected by this anatomy
- **Imaging Pearls** - How this appears on X-ray, CT, MRI

#### Example Structure:

```javascript
{
    id: "pancreatic-anatomy-histology",
    name: "Pancreatic Anatomy & Histology",
    system: "endocrine",
    categories: ["anatomy", "endocrine-anatomy"],
    tags: ["anatomy", "histology", "pancreas"],
    pageType: "anatomy",
    detail: {
        grossAnatomy: "Retroperitoneal organ in upper abdomen. Head (C-loop of duodenum), neck, body, tail (extends to splenic hilum). Dual function: EXOCRINE (acinar cells 98%) and ENDOCRINE (islets of Langerhans 2%)...",

        histology: `
## Islets of Langerhans (Endocrine)
- **Beta cells (70%)**: Insulin secretion. Located centrally in islet.
- **Alpha cells (20%)**: Glucagon secretion. Peripheral in islet.
- **Delta cells (5-10%)**: Somatostatin secretion. Scattered.
- **PP cells (<5%)**: Pancreatic polypeptide. Scattered.
        `,

        embryology: "Develops from foregut endoderm week 4-5. Dorsal and ventral pancreatic buds fuse. Ventral bud rotates ‚Üí forms uncinate process + inferior head. Dorsal bud ‚Üí body, tail, superior head...",

        clinicalCorrelations: [
            "**Type 1 DM**: Autoimmune destruction of beta cells ‚Üí insulitis (lymphocytic infiltration of islets)",
            "**Type 2 DM**: Beta cell dysfunction + amyloid deposition (amylin aggregates)",
            "**Pancreatic cancer**: Head tumors (70%) ‚Üí obstructive jaundice (compresses common bile duct)",
            "**Annular pancreas**: Embryologic malformation ‚Üí duodenal obstruction in neonates"
        ],

        relatedDiseases: [
            "type-1-diabetes-mellitus",
            "type-2-diabetes-mellitus",
            "acute-pancreatitis",
            "chronic-pancreatitis",
            "pancreatic-adenocarcinoma"
        ]
    }
}
```

#### Estimated Anatomy Topics by System:
- **Cardiovascular**: 20-25 topics
- **Respiratory**: 10-12 topics
- **Gastrointestinal**: 25-30 topics
- **Neurology**: 30-40 topics (most anatomy-heavy)
- **Musculoskeletal**: 40-50 topics
- **Reproductive**: 15-20 topics

**Total Estimated Topics**: ~180-220 anatomy topics
**Estimated Time**: 200-250 hours
**Target**: Phase 8 (after Physiology Explorer complete)

---

### Implementation Timeline:

#### Interim Storage (During Conditions Expansion):
- Create `/conditions/data/physiology/` directory
- Store physiology entries with `pageType: "physiology"` tag
- These will appear in Conditions Explorer but be filterable/distinguishable
- Easy migration when Physiology Explorer built

#### Phase 7 Development (After Conditions Complete):
1. **Weeks 1-4**: Build Physiology Explorer infrastructure (navigation, UI, search)
2. **Weeks 5-20**: Populate physiology content (15-20 topics per system)
3. **Weeks 21-24**: Build cross-linking between Conditions ‚Üî Physiology ‚Üî Medications
4. **Weeks 25-26**: QA and testing

#### Phase 8 Development (After Physiology Complete):
1. **Weeks 1-4**: Build Anatomy Explorer infrastructure
2. **Weeks 5-24**: Populate anatomy content (20-25 topics per system)
3. **Weeks 25-28**: Cross-link Anatomy ‚Üî Conditions ‚Üî Physiology
4. **Weeks 29-30**: QA and testing

**Total Additional Time**: ~50-60 weeks (1 year)

---

### Cross-Linking Strategy:

Each **disease** entry will have:
```javascript
relatedPhysiology: ["insulin-secretion-regulation", "glucose-metabolism"],
relatedAnatomy: ["pancreatic-anatomy-histology"]
```

Each **medication** entry will have:
```javascript
relatedPhysiology: ["insulin-secretion-regulation"],
mechanismOfAction: "GLP-1 receptor agonist (Gs-coupled GPCR) ‚Üí ‚Üë cAMP ‚Üí glucose-dependent insulin secretion..."
```

Each **physiology** entry will have:
```javascript
relatedDiseases: ["type-1-diabetes-mellitus", "type-2-diabetes-mellitus"],
relatedMedications: ["glp1-agonists", "sulfonylureas"],
relatedAnatomy: ["pancreatic-anatomy-histology"]
```

This creates a **knowledge graph** allowing students to:
- Study disease ‚Üí understand underlying physiology ‚Üí see anatomical basis
- Study medication ‚Üí understand physiologic target ‚Üí see related diseases
- Study physiology ‚Üí see clinical applications ‚Üí understand pathophysiology

---

### Priority Rationale:

**Why AFTER Conditions Explorer completion:**
- Conditions = highest USMLE yield (60-70% of Step 1 questions)
- Physiology/Anatomy = foundation but tested via disease application
- Better to have comprehensive disease content FIRST, then add physiology context
- Prevents scope creep during core content development
- Allows proper architecture planning once Conditions structure mature

**Why separate explorers (not combined):**
- Clean separation of concerns
- Different study patterns (basic science review vs clinical application)
- Easier to navigate and search
- Scalable for future additions (Biochemistry, Biostatistics, Behavioral Science)
- Matches traditional medical curriculum structure (pre-clinical vs clinical)

---

**Document Version**: 1.1
**Created**: October 21, 2025
**Updated**: October 23, 2025
**Next Review**: Weekly

---

## üìù NOTES

- This roadmap assumes ~45 minutes per disease for Level 3 expansion
- High-yield systems (Neurology, Infectious Disease, Endocrine, Rheumatology) prioritized for USMLE Step 1 relevance
- Format standardization integrated into respective phase work to avoid duplicate effort
- Category pages deferred until Phase 2 completion to ensure disease content quality first
- Physiology and Anatomy explorers deferred until ALL conditions complete (Phases 7-8)
- Timeline is flexible and can be adjusted based on progress velocity

